XPR – Lifestyle Demo
Author:
Repair Biotechnologies, Inc.
Repair Biotechnologies Granted Rare Disease Evidence Principles (RDEP) Eligibility by the FDA for REP-0003 in Homozygous Familial Hypercholesterolemia
May 12, 2026